Ozempic Gastroparesis Settlement: Criteria Explained

Latest update (2026-01)

FDA enforcement record (Ongoing): Presence of Particulate Matter: Hair was found in a prefilled syringe. [source]

From General Health Awareness to Occupational Exposure

The legacy context of general health and science information has long addressed how major societal disruptions—such as the COVID-19 pandemic—can alter personal habits, including alcohol consumption, and the importance of maintaining a balanced relationship with such substances. This heritage emphasizes awareness of how external stressors influence individual choices and the need for informed, moderate engagement with products that affect well-being. This foundational perspective now extends to a more specific domain: the widespread use of medications like Ozempic, originally developed for metabolic conditions, and the emerging focus on their potential unintended effects. In mass production environments, where these drugs are manufactured and distributed at scale, occupational exposure becomes a distinct concern. Workers handling raw materials, finished products, or byproducts may face unique risks that differ from those of end users. The transition from general health literacy to this occupational lens requires recognizing that exposure pathways—whether through inhalation, dermal contact, or ingestion in a workplace setting—demand careful scrutiny. The bridge concept here is the shift from broad health guidance to a targeted examination of how production processes can create exposure scenarios, particularly regarding gastrointestinal complications such as gastroparesis, without delving into specific disease mechanisms. This pivot maintains a neutral, academic tone while refocusing on the worker's environment.

Understanding Gastroparesis and Its Link to Ozempic

Gastroparesis is a disorder characterized by delayed gastric emptying in the absence of mechanical obstruction, leading to symptoms such as nausea, vomiting, early satiety, bloating, and abdominal pain. Clinical diagnosis typically involves gastric emptying scintigraphy, which measures the rate at which food leaves the stomach. The condition can significantly impair quality of life and may require dietary modifications, medications, or more invasive interventions. Ozempic (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist approved as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus and to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Its mechanism involves slowing gastric emptying, which contributes to its glucose-lowering effects but also raises concerns about gastrointestinal adverse effects. Clinical trial data show that gastrointestinal adverse reactions occur more frequently among patients receiving Ozempic than placebo. In pooled placebo-controlled trials, gastrointestinal adverse reactions were reported in 15.3% of placebo patients, 32.7% of those on Ozempic 0.5 mg, and 36.4% of those on Ozempic 1 mg (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). The majority of reports of nausea, vomiting, and/or diarrhea occurred during dose escalation. Discontinuation due to gastrointestinal adverse reactions occurred in 3.1% of patients on Ozempic 0.5 mg and 3.8% on Ozempic 1 mg, compared to 0.4% on placebo (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). In a trial comparing Ozempic 1 mg and 2 mg, gastrointestinal adverse reactions occurred more frequently with the 2 mg dose (34.0%) versus 1 mg (30.8%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Additional gastrointestinal adverse reactions with a frequency of less than 5% associated with Ozempic include dyspepsia (placebo 1.9%, 0.5 mg 3.5%, 1 mg 2.7%), eructation (0%, 2.7%, 1.1%), flatulence (0.8%, 0.4%, 1.5%), gastroesophageal reflux disease (0%, 1.9%, 1.5%), and gastritis (0.8%, 0.8%, 0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). While gastroparesis is not explicitly listed in these trial data, the known pharmacologic effect of GLP-1 receptor agonists to delay gastric emptying provides a mechanistic pathway linking Ozempic to gastroparesis. Delayed gastric emptying can exacerbate or unmask gastroparesis in susceptible individuals, and the reported symptoms of nausea, vomiting, dyspepsia, and gastroesophageal reflux disease are consistent with gastroparesis presentation.

Risk Considerations and Settlement Criteria

The adequacy of warnings regarding Ozempic and gastroparesis is a key risk consideration. The prescribing information for Ozempic includes warnings about gastrointestinal adverse reactions, but does not specifically mention gastroparesis as a potential adverse effect. Patients and healthcare providers may not be fully aware of the risk of developing gastroparesis while using Ozempic, particularly in those with pre-existing gastrointestinal conditions or other risk factors. This gap in specific warnings could affect informed consent and medical decision-making. For affected patients, settlement-related considerations involve documenting the timeline between Ozempic exposure and the onset of gastroparesis symptoms. Evidence of a temporal relationship is crucial for establishing causation. Patients should maintain records of when they started Ozempic, dose changes, and when gastrointestinal symptoms began. Medical documentation of gastroparesis diagnosis through gastric emptying studies or other objective measures strengthens a claim. The severity and duration of symptoms, as well as any hospitalizations or interventions required, are also relevant factors. Settlement criteria typically require proof that the patient used Ozempic as prescribed, developed gastroparesis after starting the medication, and that other causes of gastroparesis (such as diabetes itself, surgery, or other medications) were reasonably excluded. The legal landscape for such claims is evolving, and patients should consult with an attorney experienced in pharmaceutical litigation to assess their individual case. In summary, while Ozempic is effective for glycemic control and cardiovascular risk reduction, its gastrointestinal adverse effects, including the potential to cause or worsen gastroparesis, warrant careful monitoring. The absence of specific warnings about gastroparesis in the prescribing information may be a factor in settlement considerations for affected patients. Documenting the exposure timeline and obtaining a definitive diagnosis are essential steps for those pursuing claims.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is gastroparesis and how is it diagnosed?

Gastroparesis is a disorder characterized by delayed gastric emptying without mechanical obstruction, causing symptoms like nausea, vomiting, early satiety, bloating, and abdominal pain. Diagnosis typically involves gastric emptying scintigraphy, which measures the rate at which food leaves the stomach.

What evidence links Ozempic to gastroparesis?

Ozempic (semaglutide) is a GLP-1 receptor agonist that slows gastric emptying as part of its mechanism. Clinical trials show higher rates of gastrointestinal adverse reactions with Ozempic compared to placebo, including nausea, vomiting, dyspepsia, and GERD, which are consistent with gastroparesis symptoms. While gastroparesis is not explicitly listed, the pharmacologic effect provides a plausible link.

What are the settlement criteria for Ozempic-related gastroparesis?

Settlement criteria typically require proof of Ozempic use as prescribed, development of gastroparesis after starting the medication, and reasonable exclusion of other causes such as diabetes, surgery, or other medications. Documentation of the exposure timeline and objective diagnosis via gastric emptying studies is essential.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Ozempic exposure and a confirmed Gastroparesis diagnosis may request an independent eligibility review. [Begin Assessment]

References

DailyMed Ozempic Prescribing Information

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.